<DOC>
	<DOC>NCT01169558</DOC>
	<brief_summary>This expanded access study will assess the safety and efficacy of intravenous bevacizumab (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks) in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum. The anticipated time on study treatment is 3-12 months.</brief_summary>
	<brief_title>A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Previously untreated metastatic colon or rectal cancer; Scheduled to begin fluoropyrimidinebased chemotherapy as a first line treatment. Prior chemotherapy for metastatic colon or rectal cancer; Planned radiotherapy for underlying disease; central nervous system metastases; Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before study start.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>